Table 1.
Patient characteristics
| Tofacitinib 5 mg two times per day | Tofacitinib 10 mg two times per day | Total | |
| Number of patients (n) | 15 | 15 | 30 |
| Disease duration (years), mean±SD (range) | 6.3±4.7 (1–15) | 7.1±4.9 (2–21) | 7.7±5.0 (1–21) |
| Age (years), mean±SD (range) | 52.3±11.4 (27–69) | 53.3±8.8 (34–69) | 52.8±10.0 (27–69) |
| Female sex, n (%) | 14 (93) | 13 (87) | 27 (90) |
| DAS28 (baseline), mean±SD | 4.80±0.69 | 5.29±0.79 | 5.05±0.77 |
| RF positivity, n (%) | 12 (80) | 12 (80) | 24 (80) |
| ACPA positivity, n (%) | 13 (87) | 11 (73) | 24 (80) |
| Smoking (current) (n) | 4 | 3 | 7 |
| Patients with comorbidity (n) | |||
| Cardiovascular disease | 3 | 3 | 6 |
| Hypertension | 5 | 10 | 15 |
| Diabetes mellitus | 1 | 1 | 2 |
| Gout | 1 | 2 | 3 |
| Anxiety | 0 | 2 | 2 |
| Hypothyroidism | 3 | 2 | 5 |
| Previous malignancy | 2 | 0 | 2 |
| Osteoporosis | 1 | 2 | 3 |
| Concomitant use of csDMARDs (n) | 12 | 11 | 23 |
| MTX | 9 | 7 | 16 |
| Sulfasalazine | 0 | 1 | 1 |
| Leflunomide | 2 | 2 | 4 |
| MTX +sulfasalazine | 1 | 0 | 1 |
| Leflunomide +sulfasalazine | 0 | 1 | 1 |
| Concomitant use of corticosteroids (n) | 4 | 6 | 10 |
ACPA, anticitrullinated protein antibody; csDMARD, conventional synthetic disease-modifying antirheumatic drug; DAS28, 28-Joint Disease Activity Score; MTX, methotrexate; RF, rheumatoid factor.